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Statement of Significance: Metabolic imaging with hyperpolarized [1-
13C]pyruvate detects low levels of c-Myc-driven glycolysis in patient-derived 
glioblastoma models which, when translated to the clinic, could be used to 
detect occult disease, determine disease prognosis, and target radiotherapy.  
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Abstract 
13C magnetic resonance imaging (MRI) of hyperpolarized [1-13C]pyruvate 
metabolism has been used in oncology to detect disease, investigate disease 
progression, and monitor response to treatment with a view to guiding 
treatment in individual patients. This technique has translated to the clinic with 
initial studies in prostate cancer. Here we use the technique to investigate its 
potential uses in patients with glioblastoma (GB). We assessed the 
metabolism of hyperpolarized [1-13C]pyruvate in an orthotopically implanted 
cell line model (U87) of GB and in patient-derived tumors, where these were 
produced by orthotopic implantation of cells derived from different patients. 
Lactate labeling was higher in the U87 tumor when compared to patient-
derived tumors, which displayed inter-tumoral heterogeneity, reflecting the 
intra- and inter-tumoral heterogeneity in the patients' tumors from which they 
were derived. Labeling in some patient-derived tumors could be observed 
before their appearance in morphological images, while in other tumors it was 
not significantly greater than the surrounding brain. Increased lactate labeling 
in tumors correlated with c-Myc driven expression of hexokinase 2 (HK2), 
lactate dehydrogenase A (LDHA) and the monocarboxylate transporters 
(MCT) and was accompanied by increased radio-resistance. Since c-Myc 
expression correlates with glioma grade, this study demonstrates that imaging 
with hyperpolarized [1-13C]pyruvate could be used clinically with GB patients 
to determine disease prognosis, to detect early responses to drugs that 
modulate c-Myc expression and to select tumors, and regions of tumors, for 
increased radiotherapy dose. 
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Introduction 
Gliomas represent 80% of primary tumors affecting the adult human central 
nervous system and are classified into four types. The most aggressive, grade 
IV glioblastoma (GB), accounts for more than 50% of all diagnosed adult 
gliomas (1,2).   De-bulking surgery followed by radiotherapy with concomitant 
administration of temozolomide is the current standard of care treatment (3), 
however median survival is only 15 months (4).    The tumor is driven by 
multiple genetic alterations, including loss of the phosphatase and tensin 
homolog (PTEN) gene, amplification of the epidermal growth factor receptor 
(EGFR), and increased signaling via the phosphatidylinositol-3-kinase 
(PI3K)/Akt pathway (2,5).  The latter pathway is activated in more than 88% of 
cases, which results in up-regulated glucose transporter expression and 
increased glycolysis and is associated with tumor progression and resistance 
to treatment (6,7).   Expression of the transcription factor c-Myc is correlated 
with glioma grade and between 60–80% of GB exhibit elevated levels of Myc 
(8,9).   Myc also drives increased expression of the glycolytic enzymes in 
order to meet the elevated biosynthetic demands of increased cell 
proliferation (10). 
 Hyperpolarization of 13C-labeled metabolites, which can increase their 
sensitivity to magnetic resonance detection by more than 10,000x (11), has 
revolutionized our capability to image metabolism in vivo (12) and has already 
translated to the clinic (13).  Previous 13C magnetic resonance spectroscopic 
imaging (MRSI) studies of hyperpolarized [1-13C]pyruvate metabolism in 
orthotopically implanted cell line models of GB have shown much higher 
levels of labeled lactate in the tumor when compared to surrounding normal 
Research. 
on July 29, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/0008-5472.CAN-18-0759 
 5 
brain tissue (14).  The purpose of this study was to determine whether this 
was also the case in patient-derived orthotopically implanted xenograft 
(PDOX) models of GB, which more faithfully reproduce the biology of patient 
tumors than the cell line models (15,16), and to determine whether there were 
differences in pyruvate metabolism between PDOX models derived from 
different patients. 
 
Materials and Methods 
 
Assessment of intra-tumoral heterogeneity in patient tumors by 
fluorescence-guided multi-region sampling.  Intra-operative sampling of 4 
patients with confirmed GB was performed by an experienced neurosurgeon 
(CW).  Cytoreductive surgery was guided by giving the patients 5-
aminolevulinic acid (5-ALA) 6 hours prior to surgery (17). Tissue sampling 
was performed using a Zeiss OPMI Pentero operating microscope (Zeiss, 
Welwyn Garden City, UK) for fluorescence detection of protoporphyrin IX (a 5-
ALA metabolite) (Zeiss) (18).  Written informed consent was obtained from the 
patients, the studies were conducted in accordance with the Declaration of 
Helsinki and were approved by an institutional review board. 
 
Cell culture.  Brain tumor tissue was collected from GB patients using 
protocols compliant with the UK Human Tissue Act 2004 (HTA licence ref 
12315), approved by the Local Regional Ethics Committee (LREC ref 
04/Q0108/60) and in accordance with the Declaration of Helsinki. Informed 
consent was obtained from each patient. Tumor tissue was disaggregated in 
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phosphate-buffered saline (PBS) and cells isolated by filtration through a 40 
μm filter (Falcon, UK) and washed with 10 mL red blood cell lysis buffer 
(Abcam, UK). Cell viability was assessed by Trypan blue dye exclusion and 
viable cells were seeded at 15,000 cells cm2 and grown as monolayer 
cultures on extracellular matrix (ECM)-coated T75 flasks (Engelbreth-Holm-
Swarm murine sarcoma ECM gel – 1:10 dilution, Sigma, UK) in phenol red-
free Neurobasal A (Gibco, UK) medium containing 20 mM L-glutamine 
(Sigma, UK), 1% Streptomycin/Penicillin/Amphotericin B (Invitrogen, UK), 20 
ng/mL hEGF (Sigma, UK), 20 ng/mL hFGF (R&D systems, UK), 2% B27 
(Invitrogen, UK) and 1% N2 (Invitrogen, UK). U87 cells (American Tissue 
Culture Collection, Manassas, US) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 2 mM L-glutamine  and 10% fetal bovine 
serum (Gibco, UK). Cell line authentication was performed using STR 
genotyping contemporaneously with the experiments. Cells were used within 
3 passages of being thawed. Mycoplasma testing was performed using RNA-
capture ELISA.  
 
Generation of cell lines expressing doxycycline-inducible shRNA 
targeting c-Myc.  Short hairpin (sh)RNA sequences targeting c-MYC were 
cloned into the doxycycline-inducible TetOnPLKO lentiviral vector (Addgene) 
(19,20) using the following oligonucleotides: 
shMYC seq F: 
5’- 
CCGGCCTGAGACAGATCAGCAACAACTCGAGTTGTTGCTGATCTGTCTC
AGGTTTTTG 
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shMYC seq R: 
5’ –
AATTCAAAAACCTGAGACAGATCAGCAACAACTCGAGTTGTTGCTGATCT
GTCTCAGG 
The control sequences were: 
shCtrl F: 
5’- 
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTT
AGG 
shCtrl R: 
5’ - 
AATTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTT
AGG 
Lentiviruses were produced by co-transfecting HEK 293T cells with the 
shRNA plasmid and the packaging plasmids pCMVΔR8.91 (gag-pol) and 
pMD.G (VSV-G glycoprotein) (21). Supernatants containing lentiviruses were 
collected 72 h after transfection, mixed with polybrene (8 μg/ml) and used to 
infect GB4 cells. Fresh medium containing puromycin (2 μg/ml) was added 
after 24 h and cells were selected for at least 48 h.  
 
c-Myc knock down.  Transduced GB4 cells were grown in 6 well plates to 
approximately 50% confluency in serum-free medium. Cells were then 
incubated with doxycycline (10 ng/mL) for 48 h in serum-free medium, 
harvested and protein extracted for western blot analysis to confirm knock 
down of c-Myc and determine the concentrations of LDHA and HK2.  
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Orthotopic tumor model.  Procedures were performed in compliance with 
project and personal licenses issued under the United Kingdom Animals 
(Scientific Procedures) Act, 1986 and were approved by the Cancer Research 
UK, Cambridge Institute Animal Welfare and Ethical Review Body. Tumors 
were created by intracranial implantation of cells in 6 week-old (200-250 g) 
female rnu/rnu athymic nude rats (Charles River, Germany; Harlan, UK). 
Cells, below passage 20, were counted and assessed for viability (Vi-CELL 
XR, Beckman Coulter, Brea, US) before re-suspension in culture media at 2 x 
106 cells μL-1. Animals were anaesthetized by inhalation of 1-2% isoflurane 
(Isoflo, Abbotts Laboratories Ltd., UK) in O2 (flow rate 2 L min
-1). Analgesia, 
administered subcutaneously (Vetergesic (Alstoe, York, UK), contained 0.3 
mg/mL buprenorphine hydrochloride and 0.135% w/v chlorocresol diluted 1:10 
in 0.9% sodium chloride, and 1 mL/kg of subcutaneous Rimadyl LA (Pfizer, 
New York, US) containing carpofen (Zoetis, Florham Park, NJ, US) (5 mg/kg 
diluted 1: 10 in 0.9% sodium chloride). Animals were placed in a stereotactic 
surgical frame (Kopf, Tujunga, US) and a 1 mm hole drilled 2 mm anterior and 
3 mm lateral to the bregma (right-side).  Five μL of the cell suspension were 
delivered 6 mm intracranially via a 23-gauge full displacement syringe (SGE 
Analytical Science, Melbourne, Australia).  
 
Magnetic Resonance Imaging.  MR experiments were performed using a 7T 
spectrometer (Agilent, Palo Alto, US). Animals were anesthetized following 
inhalation of 1-2% isoflurane in O2 (flow rate 2 L min
-1) and core body 
temperature, breathing and heart rate were monitored (SA instruments Inc., 
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Stonybrook, US). Axial 1H MR (T2-weighted) images were acquired using a 72 
mm inner-diameter 1H quadrature birdcage coil (Rapid Biomedical GMBH, 
Rimpar, Germany) and a fast spin-echo pulse sequence (TR, 1500 ms; TE, 
40 ms across a matrix of 256 x 256 data points with a field of view (FOV) of 
40 x 40 mm and 4-8 averages). Slice thickness was 2 mm and 15 contiguous 
slices were obtained. Contrast agent-enhanced images were acquired using a 
T1-weighted spoiled-gradient-echo sequence prior to and then 90 seconds 
after injection of 100 μmol/kg Dotarem (Guebert). Images consisted of 5 slices 
1.5 mm thick with gaps of 0.3 mm centered on the tumor with TR 43 ms, TE 
4.6 ms, 27° flip angle and 4 averages. The field of view was 40 mm x 40 mm 
with a 256 x 128 data matrix. 
 
Proton magnetic resonance spectroscopy.  Lactate spectra were acquired 
from single 4 x 4 x 4 mm voxels using LASER acquisition (22) and VAPOR 
water suppression (23) pulse sequences and the 72 mm diameter volume coil 
for transmit and a quadrature coil placed over the rat’s head for receive 
(Rapid Biomedical, Rimpar, Germany). Spectra were acquired with echo 
times (TE) of 37 and 144 ms and 512 averages, or 1024 averages for the 
longer TE. In one tumor an extra spectrum was acquired with TE 288 ms and 
1024 averages.  Water reference spectra were acquired at a TE of 37 ms and 
using 16 averages.  Spectral regions between 1 and 1.6 ppm was least-
squares fitted to a model of a lactate methyl resonance doublet, at all three 
echo times, and a broad lipid methylene resonance at TE=37 ms. This fitting 
was also used to calculate the lactate methyl resonance T2. The water T2 was 
measured using STEAM localization, using 16 TE values between 0.005 and 
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0.50 seconds and 16 averages.  The lactate methyl and water T2s were used 
to estimate their respective intensities at TE=0. Assuming a tissue water 
concentration of 46 M (24), these intensities were used to estimate a lactate 
concentration. Similar water and lactate spectra were acquired from 6 x 8 x 4 
mm voxels in normal brain; 512 averages at TE=37 ms and 1024 at TE=144 s 
for the lactate spectra and 16 averages at TE=37 ms for the water spectra. 
The same T2 value for lactate and a mean value for the water T2 in the tumors 
were used for concentration calculations.  Data were processed in MATLAB 
(Mathworks, Natick, USA). 
   
Dynamic nuclear hyperpolarization.  [1-13C]pyruvic acid (82 mg) containing 
15 mM trityl radical, tris(8-carboxy2,2,6,6-tetra-(hydroxyethyl)-benzo-[1,2-
4,50]-bis-(1,3)-dithiole-4-yl)-methyl sodium salt (OXO63; both GE Healthcare) 
was mixed with 1.5 mM of gadoterate meglumine (Guerbet) and polarized as 
described previously (25). After dissolution this gave a 184 mM 
hyperpolarized [1-13C]pyruvate solution at room temperature with a pH of 7.2 
and between 17 and 21% polarization.  
 
13C magnetic resonance spectroscopic imaging.  13C spectroscopic 
images were acquired using a 20 mm diameter transmit/receive surface coil 
(Varian, Palo Alto, US) inside the 72 mm diameter 1H volume coil and 
positioned under the supine rat head. T2-weighted 
1H images were used to 
define a 6 mm slice that incorporated the maximum dimensions of the tumor. 
A slice-selective shim was then performed. Hyperpolarized [1-13C]pyruvate 
was injected via a tail vein cannula, which took approximately 10 s.  Single 
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time point axial 13C chemical shift images were obtained from the 6 mm slice, 
where image acquisition started 20 s after pyruvate injection (TR 30 ms; TE 
1.2 ms; FOV 40 x 40mm; data matrix 32 x 32; sinc excitation pulse with 
approximate 5º flip angle at 13 mm from the surface coil; spectral width 6010 
Hz; acquisition time 21.3 ms; 128 complex data point pairs; with phase-
encoding gradients preceding signal acquisition). Lactate-to-pyruvate ratios 
were calculated using an in-house MATLAB script. Voxels were included if the 
signal was 3.5 times the standard deviation determined from 100 voxels in 
noise regions, and if there was an adjacent voxel that met this criterion.  
Areas under the peaks were calculated by time domain fitting of the 
resonances after spatial Fourier transformation.  Animals implanted with GB4 
c-myc KD cells were imaged when tumors were >0.1 cm3.  They were then 
fed a doxycycline diet for 1 week and re-imaged (Doxycycline diet, 0.2 g/kg 
food pellet, Harlan D.98186). 
 
Determination of sensitivity to radiotherapy.  GB1 and GB4 cell lines were 
grown in duplicate to 50% confluence and then treated with a single dose (15 
Gy) of radiotherapy using a Cs-137 irradiator (IBL 637; CIS Bio International, 
Saclay, France).  Cell viability was determined using an automated Trypan 
blue dye exclusion assay (ViCell, Beckman Coulter, US) at 1, 3, 5 and 7 days 
after irradiation. 
 
GB4 control cells, which included non-transduced cells and cells transduced 
with a lentivral vector expressing a doxycycline-inducible control shRNA, and 
GB4 cells expressing a doxycycline-inducible shRNA targeting c-Myc (GB4 c-
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myc KD) were grown to approximately 50% confluence in serum-free media.  
They were then treated with either doxycycline (10 ng/mL) alone or 
doxycycline (10 ng/mL) for 48 h before treatment with a single dose of 15 Gy 
and cell viability determined. 
 
GB4 tumor-bearing rats were treated 24 h after imaging with hyperpolarized 
[1-13C]pyruvate. Rats were anaesthetized using inhalation anesthesia and a 
lead collimator was used to protect the snout and body. Animals were 
wrapped in insulating plastic and silver foil to maintain body temperature and 
Lubrithal (Dechra, Leakwood, US) was applied for eye protection. For low 
dose therapy Temozolomide (100 mg kg-1) was dissolved in 1 mL water and 
administered by oral gavage 1 hour prior to radiotherapy. Radiotherapy (15 
Gy) was delivered over 825 s using a Cs-137 irradiator (IBL 637; CIS Bio 
International, Saclay, France). The Temozolomide dose was split so that 50 
mg kg-1 was given 1 hour prior to the first fraction of radiotherapy (15 Gy) and 
also 1 hour prior to the second fraction (15 Gy) 72 h later. A further 10 Gy 
radiation dose was given at 72 h later giving a total of 40 Gy and 100 mg kg-1 
of Temozolomide. 
 
Histopathology and immunohistochemistry.  Brains were excised and 
immediately placed in 10% formalin (Sigma-Aldrich, St Louis, US) for 24 h, 
then in 70% ethanol and then sectioned. Hematoxylin and eosin staining 
(H&E) (ST020 Multistainer – Leica Microsystems, Wetzlar, Germany) was 
performed on 5 μm sections, which were cut using the surface injection site 
as a guide for the center of the underlying tumor. Further 10 μm sections were 
Research. 
on July 29, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/0008-5472.CAN-18-0759 
 13 
taken for TUNEL staining and immunohistochemistry (IHC). TUNEL was 
performed using Leica’s Polymer Kit (Leica Microsystems, Wetzlar, Germany) 
and Promega’s DeadEnd Colorimetric TUNEL System (Promega, Madison, 
US). IHC was performed using Leica’s Polymer Refine Kit and human-specific 
antibodies. Specifically; Ki67 – 1:200 dilution (M7240, Dako, Espoo, Finland), 
Monocarboxylate Transporter (MCT) 1 – 1:500 dilution (HPA003324, Atlas, 
Stockholm, Sweden), MCT 4 – 1:500 dilution (HPA021451, Atlas, Stockholm, 
Sweden), Glial Fibrillary Acid Protein (GFAP) – 1:10,000 dilution (Z0334, 
Dako, Espoo, Finland), c-Myc – 1:50 dilution (ab32072, Abcam, UK), pAKT – 
1:25 dilution (3787, Cell Signalling Technology, Danvers, US). Images were 
analyzed using Aperio image viewing software using in-house algorithms. 
 
Western blotting.  Protein was extracted from cell and tissue samples in 
Pierce RIPA buffer, containing protease inhibitor and EDTA (Thermo Fisher, 
US). Cell disruption was performed using either sonication (cell culture) 
(Bioruptor, Diagenode, Liege, Belgium) or via homogenization (tissues) 
(Precellys, Bertin, Rockville, US). Proteins were separated using gel 
electrophoresis in NuPage Bis-Tris precast gels (Thermo Fisher, Waltham, 
US) and dry-blotted onto polyvinylidene difluoride (PVDF) membranes using 
an iBlot transfer stack (Thermo Fisher, Waltham, US). Subsequent analysis 
was performed using the Odyssey Licor near-infrared digital fluorescence 
imaging system (Licor biotechnology, Lincoln, NE, US). Samples were 
analyzed in duplicate or triplicate and data from technical replicates were 
averaged. Antibodies were used at manufacturer recommended dilutions: c-
Myc – Abcam ab32072 1:10000; pAKT Cell Signalling Technology #9271 
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1:1000; HK2 – Cell Signalling Technology #2106 1:1000; LDHA – Cell 
Signalling Technology #3582 1:1000. 
 
Whole exome sequencing.  Massively parallel sequencing exome capture 
was performed using Illumina Nextera Rapid Capture, according to the 
manufacturer’s protocol. Fragment size was confirmed using a Bioanalyser 
(DNA1000 chip) before pre-capture pooling and qPCR, using the KAPA 
Quantification Kit, to confirm DNA concentration. Exome sequencing was 
performed on an Illumina HiSeq 2500 using v4 chemistry generating 125-bp 
paired-end reads with dual indexing. Variant calling used a pipeline based on 
Burrows-Wheeler Aligner (BWA). BWA-mem was used for mapping 
sequencing reads to the human reference genome (GRCh37) (26).  The 
genome analysis toolkit (GATK) (version 3.5) was then used to apply local 
indel realignment and to recalibrate base quality scores (27). Variant calling 
was carried out jointly using the GATK HaplotypeCaller. Annotation of variants 
was accomplished using ANNOVAR(28). Oncotator was used for further 
annotation of candidate variants with cancer relevant annotations (29). 
 
Statistics.  All statistics were performed using GraphPad Prism (GraphPad 
Software Inc, California, US) and MATLAB (MathWorks, Massachusetts, US).  
 
Results 
Patient-derived orthotopic xenografts resemble the human disease 
 Derivation of the cell lines and the conditions used to culture them have 
been shown to give GB PDOX models that recapitulate the biology of the 
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tumors from which they were derived (15,16). The four models studied, 
originating from four individual GB patients, showed variable growth rates and 
grew more slowly than the U87 cell line model (30) (Fig. 1 a).  These models 
reproduced the morphology of the patient tumors, for example GB4 had a 
minimally infiltrative margin compared to GB2, in both the patient tumor and 
corresponding PDOX (Suppl. Fig 1a).  The models showed high expression 
of a glial cell marker (GFAP) (31) in vivo (Fig. 1 b) and a neural stem cell 
marker (nestin) in vitro (15) (Fig. 1 c).  U87 showed negligible expression of 
either marker.  Exome sequencing showed PTEN frameshift mutations in GB1 
– 3 tumors, which resulted in protein loss (Suppl. Fig. 1 b), and in GB4 a 
frameshift (fs) mutation in PIK3R1 (V73fs), which encodes the regulatory 
protein p85α and that could lead to activation of PI3K (5,32) (Suppl. Table 1).  
Consistent with these observations, all the models showed activation of the 
PI3K/Akt pathway, as indicated by phosphorylation of Akt (pAkt) (Suppl. Fig 1 
c).  
 
A patient-derived orthotopic xenograft showed increased lactate 
labeling when compared to normal brain 
 13C images of non tumor-bearing animals showed low intensity signals 
from lactate (Fig. 1 d). At 1 month after implantation of GB4 cells the 
hyperpolarized [1-13C]lactate/[1-13C]pyruvate signal ratio (LPR) increased 
significantly in the hemisphere containing injected cells (Fig. 1 e) compared to 
the contralateral hemisphere (n=11, *p=0.02, paired t-test) (Fig. 1f). There 
was no difference in non-injected controls (n=6, p=0.9, paired t-test) (Fig. 1g). 
LPR was significantly elevated in the right lower brain quadrant, containing 
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cells, when compared to the left lower quadrant (Fig. 1h) (n=11, *p=0.01, 
paired t-test). There was no difference in the upper right and left quadrants 
(Fig. 1 i).  Since the cell injection needle passed through the upper right 
quadrant, where there was no change in LPR, the increased LPR in the lower 
right quadrant could not simply be the result of tissue damage.  At this stage 
no tumor was visible in T2-weighted 
1H MR images of tissue water (Fig. 1 j) 
and there was no signal enhancement in T1-weighted images following 
contrast agent injection (Fig. 1 k,l). 
 
Tumors derived from different patients showed variable levels of lactate 
labeling  
 LPRs measured in tumor-containing regions, identified by hyperintensity 
on T2-weighted 
1H images, were significantly higher in GB3 and GB4 tumors, 
whereas GB1 and GB2 tumors showed an LPR similar to normal brain (Fig. 
2).  Images were acquired when tumors were ~0.1 cm3 or greater.  However, 
GB4 tumors were generally larger than GB1 tumors (*p=0.03, GB4 n=12, GB1 
n=5, unpaired t-test) (Suppl. Fig 1 d) and therefore to eliminate the potential 
confounding effect of tumor size on LPR we removed from the analysis all 
those tumors above a threshold size of 0.35 cm3.  When this was done there 
was no longer a significant difference in volume between GB1 and GB4 
tumors (p=0.3, GB4 n=7, GB1 n=6, unpaired t-test) (Suppl. Fig 1 e) but the 
difference in LPR between GB1 and GB4 was maintained (p=0.001, GB4: 
n=7, GB1: n=6, unpaired t-test) (Suppl. Fig 1 f).  The variability in labeling in 
the GB4 model, although large, is comparable with that observed previously in 
U87 tumors in mice (33). 
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Lactate labeling correlated with c-Myc expression 
 Lactate labeling depends upon pyruvate delivery (34), lactate 
concentration and the activities of LDH (35) and the monocarboxylate 
transporters (MCTs) (35,36).   Expression of the MCTs and enzymes in the 
glycolytic pathway, including LDHA and HK2, is driven by c-Myc (10). The 
concentrations of c-Myc, LDHA and HK2 were higher in GB3 and GB4 
tumors, which showed high levels of lactate labeling, than in GB1 and GB2 
tumors (Fig. 3 a-e).  This trend, however, was not repeated in cell culture, 
where GB3 cells showed lower levels of c-Myc than GB2 but comparable 
levels of LDHA and HK2 (Fig. 3 f-h; Suppl. Fig. 2 a-f).  This does not appear 
to be due to hypoxia since none of the four PDOX models shown here (GB1 – 
GB4) expressed HIF-1α in vivo (Suppl. Fig. 2 g), and only one (GB5), out of 
the 5 PDOXs studied, expressed HIF-1α in vivo (Suppl. Fig. 2 g).   None of 
the cell lines expressed HIF-1α in culture (Suppl. Fig. 2 h)).  Localized proton 
spectroscopy measurements gave GB4 tumor lactate concentrations of 2 – 8 
mM (n=4), as compared to ≤2 mM in normal rat cortex (n=2), consistent with 
an association between increased HK2 levels and aerobic glycolysis in 
glioblastoma (32).  Proton spectra of the brains of two of the four GB4 tumor-
bearing animals and spectra from the brains of the two non tumor-bearing 
animals are shown in Suppl. Fig. 3.  Increased plasma membrane expression 
of MCTs, a negative prognostic factor in the clinic (37), was observed in 
tumors with a high LPR (MCT1 in GB3 and GB4 and MCT4 in GB4) (Fig. 3 i).   
 Expression of c-Myc (38) and HK2 (39) have been associated with a 
worse prognosis.  We observed a positive correlation between c-Myc 
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expression and LPR (n=2 per GB cohort, r2=0.83, **p=0.0017, linear 
regression) (Figure 3 j), and a correlation, although poorer, between growth 
rate (Fig. 1a) and c-Myc expression (Figure 3 a,d,e), with GB1 tumors 
showing comparable growth rates to GB3 tumors and only slightly lower 
growth rates than GB4 tumors.   However, there was no correlation between 
tumor growth rate and cell proliferation, as assessed by Ki67 staining, with 
slower growing GB1 tumors, with low c-Myc expression, showing significantly 
(p<0.0001) higher levels of Ki67 staining (Suppl. Fig. 2i) than faster growing 
GB4 tumors, with high c-Myc expression.  The reasons for this discrepancy 
between tumor cell proliferation and tumor growth rate are unclear but cannot 
be explained by higher rates of cell turnover in GB1 tumors since there was 
no difference in the levels of cell death (TUNEL staining) between untreated 
GB1 and GB4 tumors (Suppl. Fig. 2 j). 
 Inhibition of the PI3K/Akt pathway has been shown previously to 
decrease GB lactate labeling in animal models injected with hyperpolarized 
[1-13C]pyruvate (14).    However, here there was a negative correlation 
between the levels of pAKT and LPR (n=2 per GB cohort, r2=0.76, p=0.0047) 
(Fig 3 k). 
 We confirmed that c-Myc-driven expression of LDHA and HK2 was 
responsible for increased lactate labeling by knocking down c-Myc expression 
in GB4 cells.  Doxycycline treatment of GB4 cells expressing a doxycycline-
inducible shRNA targeting c-Myc (GB4 c-Myc KD) substantially decreased c-
Myc, LDHA and HK2 expression (Fig 4 a-c), and in tumors derived from these 
cells LPR was decreased at 7 days after addition of doxycycline to the diet of 
tumor-bearing animals (Fig. 4 d-f). 
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Variable lactate labeling in the tumor models reflects intra- and inter-
tumoral heterogeneity in GB patients 
 Lactate labeling and c-Myc, LDHA, HK2 and MCT expression were 
reproducible between PDOXs derived from the same patient but different to 
those derived from other patients. To determine whether this was due to inter- 
or intratumoral heterogeneity we conducted 5ALA fluorescence-guided multi-
region tumor sampling (40) in four GB patients. The levels of c-Myc, HK2 and 
LDHA varied between 3 – 5 spatially disparate samples (Suppl. Fig. 4 a-g), 
indicating that PDOX heterogeneity reflects patient intra- as well as inter-
tumoral heterogeneity. As in the PDOX models, LDHA and HK2 expression 
was correlated with c-Myc expression (Suppl. Fig. 4 h,i) (3-5 regions per 
tumor, 2 technical replicates per location, r2=0.30, p=0.036 and r2=0.27, 
p=0.048 respectively). 
 
Inhibition of c-Myc expression increased radiosensitivity in cultured 
cells 
 Expression of HK2 and LDHA have been negatively correlated with 
radiosensitivity (39,41), suggesting that metabolic imaging with hyperpolarized 
[1-13C]pyruvate could be used to target increased radiotherapy dose to areas 
of radio-resistance. We investigated this by comparing the effects of 
irradiation on GB4 and GB1 cells. Following irradiation, GB4 cells, which have 
a high LPR in vivo (Fig. 2f) and high c-Myc expression in vitro and in vivo 
(Fig. 3 a,d), showed a greater preservation of viability than GB1 cells (Fig. 4 
g, p<0.0001), which have a lower LPR in vivo (Fig. 2f) and lower levels of c-
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Myc in vitro and in vivo (Fig. 3 a,d).  Doxycycline-induced c-Myc knock down 
in GB4 cells resulted in a greater decrease in cell viability following irradiation 
(Fig. 4 h). Control cells (non-transduced cells or cells transduced with a 
control shRNA) showed no significant difference in viability following 
irradiation in the presence or absence of doxycycline (Suppl. Fig. 5). 
 
 
Radiotherapy results in decreased lactate labeling in GB4 tumors 
 GB4 tumors responded to radiotherapy and Temozolomide treatment 
with a decrease in LPR 72 h after treatment (p=0.038, n=6, paired t-test) (Fig. 
4 i – k). TUNEL staining of excised tumor sections showed that this was 
accompanied by significant increases in cell death (p=0.0089, n=11 untreated 
n=8 treated, unpaired t-test) (Fig. 4 l). 
 
Discussion 
 
Studies in human brain tumors and in patient-derived GB xenografts 
implanted orthotopically in immune-compromised mice have shown that 
contrary to expectations, where the tumors were expected to be 
predominantly glycolytic, there was extensive oxidation of glucose in the 
tricarboxylic acid (TCA) cycle (42,43).   In these experiments the patients and 
mice were infused with 13C-labeled glucose immediately prior to tumor 
resection and the 13C-labeling patterns in tumor metabolites were analyzed by 
13C NMR measurements on tumor extracts.  The relatively low levels of 
lactate labeling observed in the PDOX models used here, which were similar 
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to those observed in normal brain, are consistent with these previous studies.   
The much higher levels of lactate labeling observed in the established cell line 
model used here (U87), and in the GB cell line models used in previous 
studies with hyperpolarized [1-13C]pyruvate (14), which have been shown to 
be poor models of human brain tumors (15),  reflects presumably their 
extended lifetime in culture and their very high rates of proliferation rather 
than being a necessary feature of malignancy. Previous studies with 
hyperpolarized [1-13C]pyruvate in these cell line models of glioma may, 
therefore, be overestimating the levels of labeled lactate that are likely to be 
observed in the clinic.  The PDOX models used here, which showed much 
higher levels of expression of glial (GFAP) and neural stem cell (nestin) 
markers than the U87 model, are more representative of the human disease. 
 
The patterns of lactate labeling were reproducible between GB PDOXs 
derived from the same patient but different to those derived from other 
patients.  Multi-region sampling of individual GB patients showed this likely 
reflected inter and intra-tumoral heterogeneity (40).  The relatively low levels 
of lactate labeling in the PDOXs has important implications for translation of 
this technique to the clinic since it suggests that some tumors, or some 
regions of tumors, may show lactate labeling that is indistinguishable from 
labeling in normal brain.  However, the observation of increased lactate 
labeling in brain regions where no tumor was apparent in a T2-weighted 
1H 
image of tissue morphology also suggests that the technique has the potential 
to improve tumor detection, at least in those tumors with higher levels of 
lactate labeling.   A similar observation was made in a clinical study in the 
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prostate, where lactate labeling was observed in tumor tissue that was not 
detectable in a T2-weighted 
1H image (13). 
 
Although lactate labeling levels were relatively low we nevertheless observed 
consistent differences between the different models, which could not be 
explained by differences in PI3K/Akt pathway activity but which were 
correlated with the levels of c-Myc, LDHA, HK2, and plasma membrane 
localization of MCT1 and MCT4. The role of c-Myc in determining tumor 
lactate labeling, by driving increased expression of HK2 and LDHA, was 
confirmed by knocking down c-Myc expression in GB4 tumors.  This reduced 
the expression of LDHA and HK2 and decreased lactate labeling.  The levels 
of c-Myc in GB appear to be upregulated by two complementary mechanisms: 
alternative splicing of Delta Max (44) and mTORC2-dependent 
phosphorylation and inhibition of HDACs, leading to acetylation and 
inactivation of FoxO and relief of mir-34c-dependent c-Myc suppression (38).  
In this latter study treatment of GB cells with PI3K or Akt inhibitors was shown 
to elevate c-Myc levels and increase the levels of LDHA and HK2.  Consistent 
with these observations we observed a negative correlation between the 
levels of pAkt and lactate labeling.  The patterns of c-Myc, HK2 and LDHA 
expression observed in the tumors in vivo were not entirely reproduced in the 
cells cultured in vitro.  This effect of the tumor microenvironment on gene 
expression is consistent with a recent RNAi screen of epigenetic modifiers in 
GB (45), which showed very different results when cells were grown in culture 
or as orthotopic xenografts. 
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The expression of c-Myc (8,9) and plasma membrane localization of MCT1 
and MCT4 (37) have been shown previously to correlate with tumor grade, 
increased HK2 expression has been correlated with worse overall survival 
(39) and 1H MRS measurements have demonstrated higher lactate 
concentrations in grade III and IV tumors (46).   Therefore 13C MRSI 
measurements of GB lactate labeling could provide prognostic information in 
the clinic.  Moreover, since therapeutic resistance to PI3K or Akt inhibition is 
mediated by sustained c-Myc activity (38) the technique should also be 
capable of early detection of drug resistance and response to drugs that 
modulate c-Myc expression (38,47).  The technique could potentially be used 
to select patients for metabolic therapies, for example drugs that target 
increased c-Myc driven glycolysis, such as the nicotinamide phosphoribosyl-
transferase inhibitor (NAMPT), which has demonstrated efficacy in c-Myc-
driven GB cells and in patient-derived orthotopic GB xenografts (48). 
 
Detection of response to radiotherapy has been shown previously in a rat cell 
line glioma model (C6) (25), where response was evident as a decrease in 
lactate labeling.  We have demonstrated here in GB4 tumors, which like C6 
tumors show high levels of lactate labeling, that response to concomitant 
Temozolomide and radiation treatment results in decreased in lactate 
labeling, which was explained by increased levels of cell death.  However, 
detection of response using this technique in those tumors that show much 
lower levels of lactate labeling may be challenging as the decrease in lactate 
labeling post treatment would necessarily be less.  
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Inhibition of LDHA (41) or HK2 (39) has been shown to sensitize GB cells to 
radiotherapy and we have shown that c-Myc and glycolytic enzyme 
expression are correlated with the radio-resistance of the cell lines in vitro.   
Therefore imaging with hyperpolarized [1-13C]pyruvate could potentially be 
used clinically to target increased radiotherapy dose to radio-resistant tumors 
or specific regions of tumors i.e. regions that display increased lactate 
labeling.  PET with 11C methionine, where the resolution was 4.8 mm, has 
been used to target radiotherapy in glioblastoma patients (49).   Since the 
resolution in the first clinical studies with hyperpolarized [1-13C]pyruvate in 
prostate was between 7 and 15 mm (13) this suggests that the technique may 
have sufficient spatial resolution to do this.    
 
In summary, increased levels of lactate labeling in GB PDOX models can be 
explained by increased levels of LDHA, HK2 and plasma membrane MCTs 
resulting from increased c-Myc expression.  With the recent translation of this 
technique to the clinic, metabolic imaging with hyperpolarized [1-13C]pyruvate 
could be used clinically for determining disease prognosis, for assessing 
response to drugs that are effective in reducing the levels of c-Myc and 
inducing cell death and for targeting radiation at tumor regions with high c-
Myc expression and which are expected to be radio-resistant. 
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Figure legends 
 
Figure 1  Patient-derived orthotopic xenografts (PDOX) resemble 
human glioblastoma and show increased hyperpolarized [1-
13C]lactate/[1-13C]pyruvate signal ratios when compared with normal 
brain tissue. a) Time taken from cell implantation for tumors to reach >0.05 
cm3. (GB1 n=9, GB2 n=7, GB3 n=5, GB4 n=21, U87 n=14, p<0.0001). All of 
the cell lines showed high levels of tumor initiation and growth following 
orthotopic cell implantation (GB1, 9 tumors from 9 implantations; GB2 9/9, 
GB3 5/6, GB4 23/25).  b) Percentage of cells showing immunostaining for 
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GFAP in the PDOX and U87 tumor models (GB1 n=7, GB2 n=5, GB3 n=2, 
GB4 n=19, U87 n=8). (c) Western blot of nestin expression in the indicated 
cell lines in vitro. Representative false color images of the hyperpolarized [1-
13C]lactate/[1-13C]pyruvate signal ratio (LPR) superimposed on a T2-weighted 
1H image (grayscale) of (d) a control brain (no implanted tumor cells) and (e) 
a brain one month after implantation of GB4 cells (the site of implantation is 
arrowed).  The scale bar indicates LPR. Representative T2-weighted image (j) 
and T1–weighted 
1H images before (k) and after (l) contrast agent injection 
and one month after GB4 cell implantation (the site of implantation is 
arrowed). f) LPRs averaged over the hemispheres containing implanted cells 
(right) and non-implanted (left) one month after GB4 cell implantation. The 
ratio was significantly higher in the right hemisphere (*p=0.02, n=11, paired t-
test). g) LPRs in control brains, which showed no significant difference 
between the hemispheres (p=0.9, n=6, paired t-test). LPRs averaged over the 
lower (h) and upper (i) quadrants of the indicated hemispheres one month 
after GB4 cell implantation in the right lower brain quadrant.   There was a 
significant increase in the quadrant containing implanted cells (right) (*p=0.01, 
n=11, paired t-test) but no significant difference between the upper quadrants 
(p=0.3, n=11, paired t-test).   
 
Figure 2 The different tumor models showed differences in 
hyperpolarized [1-13C]lactate/[1-13C]pyruvate signal ratios  Representative 
false color images of the hyperpolarized [1-13C]lactate/ [1-13C]pyruvate signal 
ratio (LPR) superimposed on T2-weighted 
1H images (grayscale) from animals 
implanted with (a) GB1 cells; (b) GB2 cells; (c) GB3 cells; (d) GB4 cells; (e) 
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U87 cells. Spectra from representative voxels are also shown. f) LPRs in 
tumors resulting from implantation of the indicated cell lines. Controls were 
not implanted with cells. (**p<0.009, ***p<0.0004, **** p<0.0001. (Control n=6, 
GB1 n=5, GB2 n=9, GB3 n=3, GB4 n=12, U87 n=10, unpaired t-test).  Images 
were acquired at the following times after cell implantation; GB1, 153 days; 
GB2, 322 days; GB3, 163 days; GB4, 121 days; U87,  27 days. 
 
Figure 3 Expression of c-Myc, LDH A and HK2 and MCT plasma 
membrane localisation are correlated with the hyperpolarized [1-
13C]lactate/[1-13C]pyruvate signal ratio Western blot analysis of the 
expression of c-Myc (a), LDHA (b), and HK2 (c) in the indicated tumor 
models. d) Immunohistochemical staining of c-Myc in the indicated tumor 
models and quantitative analysis of these data (e) (**p=0.009, n=2-5, 
unpaired t-test). Expression of c-Myc (f), LDHA (g) and HK2 (h) in the 
corresponding cell lines cultured in vitro (*p<0.05, **p<0.007, ***p<0.0005, 
unpaired t-test). For c-Myc there were three biological replicates and for 
LDHA and HK2 two, and two technical replicates for each sample. Band 
intensities were normalized to that for β-actin. i) Immunohistochemical 
analysis of MCT1 and MCT4 expression in the indicated tumor models; 
plasma membrane localisation is evident in GB3 and GB4 tumors. 
Correlations between LPRs measured in vivo and c-Myc expression (r2 = 
0.83, **p=0.002, n=4, linear regression) (j) and phosphorylated Akt (pAKT) (r2 
= 0.76, **p=0.005, n=4, linear regression) (k), determined by western blotting, 
in the indicated tumor models.  
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Figure 4 Inhibition of c-Myc expression decreased the 
hyperpolarized [1-13C]lactate/[1-13C]pyruvate signal ratio and increased 
radiosensitivity Expression of c-Myc, LDHA and HK2 (a – c) (normalized 
to β-actin) 48 h after addition of doxycycline (dox) to GB4 c-Myc KD cells. 
There were two biological replicates and two technical replicates per sample 
(*p<0.05, unpaired t-test). d) Change in the hyperpolarized [1-13C]lactate/[1-
13C]pyruvate signal ratios (LPRs) in tumors resulting from orthotopic 
implantation of GB4 c-Myc KD and GB4 cells one week after addition of 
doxycycline to the diet (*p=0.035, n=3, paired t-test).  LPR images, 
superimposed on grayscale 1H images, of a GB4 c-Myc KD tumor-bearing rat 
prior to (e) and after (f) addition of doxycycline to the diet. g) Response of 
GB4 and GB1 cells to 15 Gy radiation at day 0. (P<0.0001; 2 biological 
replicates, 50 technical replicates, unpaired t-test).  Viability is shown as the 
percentage of viable cells determined using an automated Trypan blue dye 
exclusion assay, as described in the methods section.  h) GB4 c-Myc KD cells 
cultured with doxycycline for 48 h prior to radiation with 15 Gy  showed a 
significant increase in the loss of cell viability (P=0.008; 4 biological replicates, 
50 technical replicates, unpaired t-test).  There was no significant difference in 
the change in viability following irradiation of GB4 cells and GB4 cells 
expressing a control shRNA between those cells that had previously been 
incubated with doxycycline and those that had not (Suppl. Fig. 5). LPR 
images superimposed on 1H images of a GB4 tumor prior to (i) and after (j) 
treatment with Temozolomide and 40 Gy of radiation. k) LPRs at 72 h after 
treatment with Temozolomide and 40 Gy of radiation (*p=0.038 n=6, paired t-
test). l) TUNEL staining of untreated tumors and tumors 72 h after treatment 
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with Temozolomide and 40 Gy of radiation (**p<0.0089, n=11 untreated, n=8 
treated, unpaired t-test). 
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